You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

adenocarcinoma of the stomach or gastro-esophageal junction

Showing 1 - 25 of 6,511
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stomach Tumors Trial in Wuhan (Fruquintinib, Sintilimab)

Not yet recruiting
  • Stomach Neoplasms
  • Wuhan, Hubei, China
    Wuhan Union Hospital, China
Nov 22, 2022

Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (AZD5863)

Recruiting
  • Gastric Cancer
  • +3 more
  • Jacksonville, Florida
  • +16 more
Aug 17, 2023

Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Chuo Ku (TRK-950, Ramucirumab,

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • TRK-950
  • +2 more
  • Chuo Ku, Japan
    Osaka International Cancer Institute
Sep 14, 2023

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach Trial in

Terminated
Has Results
  • Adenocarcinoma of the Esophagus
  • +13 more
  • oblimersen sodium
  • +2 more
  • Bronx, New York
    Montefiore Medical Center
Jan 29, 2021

Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage

Active, not recruiting
  • Clinical Stage III Gastric Cancer AJCC v8
  • +7 more
  • Duarte, California
  • +30 more
Jan 7, 2023

Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) Trial in Poland, Spain, United States (NT-I7,

Active, not recruiting
  • Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
  • Louisville, Kentucky
  • +5 more
Dec 7, 2022

Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction Trial in Amsterdam (Docetaxel, Oxaliplatin,

Active, not recruiting
  • Metastatic Gastric Cancer
  • Adenocarcinoma of the Gastro-oesophageal Junction
  • Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab
  • Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
  • Amsterdam, Netherlands
    Netherlands Cancer Institute
Jan 26, 2021

Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)

Recruiting
  • Gastric Cancer
  • +10 more
  • Kyiv, Ukraine
    National Cancer Institute
Aug 31, 2023

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (CS1001 mAb, CS1001 , Oxaliplatin)

Active, not recruiting
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • CS1001 monoclonal antibody
  • +3 more
  • Beijing, China
    Beijing Cancer Hospital
Sep 27, 2022

Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Trial in Guangzhou (zolbetuximab)

Completed
  • Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
  • Guangzhou, China
    Site CN86001
Jan 11, 2022

Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma Trial in Beijing (sintilimab, nab-paclitaxel)

Recruiting
  • Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma
  • Beijing, China
    Chinese Academy of Medical Sciences
Mar 9, 2022

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

Gastric Cancer, Gastro Esophageal Junctional Cancer, Cancer Trial (68Ga-FAPi-46)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • (no location specified)
Jun 12, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (XELOX combined with Fruquintinib and Sintilimab)

Not yet recruiting
  • Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • XELOX combined with Fruquintinib and Sintilimab
  • (no location specified)
Oct 17, 2023

Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial

Not yet recruiting
  • Advanced Esophageal Adenocarcinoma
  • +14 more
  • (no location specified)
Jan 3, 2023

Esophageal Cancer Trial (Hypofractionated radiotherapy)

Not yet recruiting
  • Esophageal Cancer
  • Hypofractionated radiotherapy
  • (no location specified)
Jan 18, 2023

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric

Completed
  • Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
  • +5 more
  • S-1 de-escalation
  • Chemotherapy by Investigator's choice
  • Heidelberg, Baden-Württemberg, Germany
    NCT-Med. Onkologie
Mar 25, 2021

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,

Recruiting
  • Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 5, 2023

Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical

Not yet recruiting
  • Clinical Stage I Esophageal Adenocarcinoma AJCC v8
  • +5 more
  • Biospecimen Collection
  • +9 more
  • Scottsdale, Arizona
  • +2 more
Oct 11, 2023

Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)

Recruiting
  • Advanced Gastric Adenocarcinoma
  • Henan, China
    Henan Tumor Hospital
Oct 13, 2022

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811;SHR-1701;capecitabine;oxaliplatin)

Not yet recruiting
  • HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jan 3, 2023

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, Beijing, China
  • +10 more
Nov 23, 2023

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

Not yet recruiting
  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jul 17, 2023